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Abstract
It has previously been reported that growth hormone
secretagogues (GHS) may have a role in the regulation of
bone metabolism in animals and humans. In this study we
evaluated the eﬀect of ghrelin, the endogenous ligand of
GHS receptors, on the proliferation rate and on osteoblast
activity in primary cultures of rat calvaria osteoblasts. In
the same experiments, we compared the eﬀects of ghrelin
with those of hexarelin (HEXA) and EP-40737, two
synthetic GHS with diﬀerent characteristics. Both ghrelin
and HEXA (1011-108 M) significantly stimulated
osteoblast proliferation at low concentrations (1010 M).
Surprisingly, EP-40737 demonstrated an antiproliferative
eﬀect at 109-108 M, whereas lower concentrations
had no eﬀect on cell proliferation. Ghrelin and HEXA
significantly increased alkaline phosphatase (ALP) and
osteocalcin (OC) production. At variance with these
peptides, EP-40737 did not significantly stimulate ALP
and OC. The mRNA for GHS-R1a receptors and the
corresponding protein were detected in calvarial osteo-
blasts by RT-PCR and Western blot respectively, indi-
cating that ghrelin and GHS may bind and activate this
specific receptor. We conclude that endogenous ghrelin
and synthetic GHS modulate proliferation and diﬀerentia-
tion of rat osteoblasts, probably by acting on their specific
receptor.
Journal of Endocrinology (2005) 184, 249–256
Introduction
Growth hormone secretagogues (GHS) are synthetic
compounds that elicit growth hormone (GH) release
both in vivo and in vitro (Locatelli & Torsello 1997)
through interaction with specific GHS receptors (GHS-R)
(Petersenn 2002). Two GHS-R mRNA isoforms pro-
duced by alternative mRNA processing have been ident-
ified so far: the full-length 1a receptor and the truncated
GHS-R1b type (Petersenn 2002). The GHS-R1a is the
functional form of the receptor that mediates the neuro-
endocrine eﬀects of GHS, whereas the functional signifi-
cance, if any, of GHS-R1b remains to be elucidated.
Recently, an endogenous ligand for GHS-R1a was cloned
from rat and human stomach, and was named ghrelin.
Ghrelin was shown to be a 28 amino acid peptide bearing
the unique acylation on the Ser3 residue (Kojima et al.
1999, 2001). Ghrelin, as well as many GHS, also partici-
pates in the regulation of energy homeostasis (Inui 2001),
cardiovascular (Bodart et al. 1999, Locatelli et al. 1999) and
gastric functions (Sibilia et al. 2002). However, the wide-
spread expression of the genes encoding ghrelin and its
cognate receptor in a variety of tissues including adrenals,
prostate, thymus, hypothalamus, hippocampus and bone
(Komatsu et al. 2000, Broglio et al. 2002, Guanapavan et al.
2002) strongly supports a potential for multiple biological
activities of ghrelin (van der Lely et al. 2004). The
possibility that ghrelin could be involved in the control of
bone metabolism is also strengthened by the observation
that gastrectomy induces osteopaenia (Bussabergher
et al. 1938, Ivy 1940, Rümenappf et al. 1997) and that
the acid-producing (oxyntic) mucosa (where ghrelin
is synthesized) is important for bone metabolism
(Lehto-Axtelius et al. 1998). Providing support for this
hypothesis, we have previously reported that hexarelin
(HEXA), a synthetic GHS, was capable of counteracting
bone loss in male gonadectomized rats (Sibilia et al. 1999).
Similarly, oral administration of GHS compounds was
reported to increase bone turnover in humans (Svensson
et al. 2001). A very interesting possibility is that the
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protective eﬀect of HEXA on bone could be due not solely
to its GH-releasing activity but also to direct eﬀects on
bone cell activities.
In this study we tested whether the latter hypothesis is
true by evaluating the eﬀect of HEXA and EP-40737
(another GHS that stimulates GH secretion but not food
intake in rats) on the proliferation rate and on osteoblast
activity in primary cultures of rat calvaria cells. In the same
experiments we compared the eﬀect of HEXA and
EP-40737 with those of ghrelin, the endogenous ligand of
GHS-R1a. Furthermore, to assess the specificity of action
of the compounds examined, the expression of GHS-R1a
in our osteoblast cell line was determined by RT-PCR
and Western blot.
Materials and Methods
Primary osteoblast cultures
All experimental protocols met the Italian Guidelines for
the Use of Laboratory Animals which conform with the
European Union Directive of November 1986 (86/609/
EEC). The primary osteoblastic cells were obtained from
rat calvariae explanted from E 21 fetuses as previously
described by Bellows and coworkers (1987) with modifi-
cations. Briefly, calvaria were finely minced and incubated
three times with 5 ml of an enzyme mixture containing
1 mg/ml collagenase type IV and 0·25% trypsin (1:250)
(Sigma-Aldrich, Italy). Dispersed cells were collected after
20 min (population 1), 30 min (population 2) and 60 min
(population 3) of incubation. An equivalent volume of
fresh enzyme was added after each cell separation. Imme-
diately after harvesting, an equal volume of Dulbecco’s
modified Eagle’s medium (DMEM, Gibco, UK) contain-
ing 10% of fetal bovine serum (FCS, Sigma-Aldrich) was
added to the cell suspension to block the enzymatic
activity. The cells were then pelleted by centrifugation,
resuspended in DMEM and the three cell populations
were pooled. The cells were then cultured in DMEM
containing 10% FCS, 1% -glutamine, 100 mg/ml peni-
cillin and 10 IU streptomycin. The cells in culture were
confirmed to be osteoblasts both by morphology and
alkaline phosphatase (ALP) expression (see below). When
confluence was reached, the medium was also supple-
mented with 50 µg/ml ascorbic acid and 3 mM
-glycerophosphate ( Sigma-Aldrich) to trigger osteoblast
diﬀerentiation.
The experiments were performed on cells at passage 6
when maximal ALP expression was found. The day before
the experiment, the culture medium was removed and
cells were maintained in DMEM without FCS for 24 h.
Cells were then incubated with fresh DMEM containing
HEXA (1011-109 M), ghrelin (1011-109 M),
EP-40737 (1011-109 M), vitamin D (Vit D) (109 M)
or FCS (10%) for 24–48 h.
[3H]Thymidine incorporation assay
The cells were plated at a density of 1·3104 cells/cm2 in
24-well plates. At confluence the cells were incubated for
24 h in DMEM without FCS. Fresh medium was then
added containing diﬀerent drugs and the cells were
incubated for 24 h. [3H]Thymidine (1 µCi/well, specific
activity 25 Ci/mmol, Amersham Pharmacia Biotech, UK)
was added during the final 2 h of incubation (Ernst et al.
1989). After washing with DMEM, cells were incubated
for 60 min with 5% cold trichloroacetic acid (Sigma-
Aldrich) and harvested. Radioactivity was measured using
a liquid scintillation counter (Wallac, Turku, Finland).
Biochemical determinations
Alkaline phosphatase The ALP activity was assessed by
measuring the release of p-nitrophenol at 37 C in 1 h
when p-nitrophenylphosphate was used as a substrate
(Sigma-Aldrich) (Farley & Jorch 1983). The enzymatic
reaction was stopped with 50 mM NaOH and absorbance
measured at A405 using an ELISA plate reader (SLT Lab
Instruments, Hillsborough, NC, USA). The results were
expressed as nmol/min/µg protein.
Osteocalcin production Quantitative determination of
osteocalcin (OC) levels was performed after 48 h incu-
bation using a rat osteocalcin EIA kit from Biomedical
Technologies, Inc. (Stoughton, MA, USA). The inter-
and intra-assay coeﬃcients of variation were 7% and 4%
respectively and the sensitivity of the assay was 0·5 ng/ml.
Values were expressed as ng/mg protein.
Proteins The total protein content was measured on
sonicated pelleted cells with the Bio-Rad Protein Assay kit
(Bio-Rad Laboratories, Richmond, CA, USA).
Total RNA isolation and RT-PCR assay
Total RNA was extracted from primary osteoblastic cells
(2106 cells/plate) according to the single-step, acid
guanidinium thiocyanate-phenol-chloroform extraction
method (Chomczynsky & Sacchi 1987). The integrity of
extracted RNA was ascertained by electrophoresis on
agarose gel. Two hundred and fifty nanograms total RNA
from each sample were subjected to reverse transcription
with Moloney murine leukaemia virus reverse tran-
scriptase (InVitrogen, Carlsbad, CA, USA) followed by
amplification using specific primers based on the published
sequence of rat GHS receptor (forward primer: AGC
GCTACTTCGCCATC; reverse primer: CCGATGAG
ACTGTAGAG). PCR analysis of total RNA yielded a
DNA fragment of the expected length for the specific
mRNA. To normalize results for diﬀerences in RNA
sampling, an aliquot of the same RT reaction was used
to amplify a rat glyceraldehyde-6-phosphate (GAPDH)
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598-bp fragment. To ensure that PCR was performed
in the linear amplification range, samples were initially
analysed after 15, 17, 20, 25, 27, 30, 35, and 40 cycles
(data not shown). For each factor, we chose the cycle
number that gave half of the maximal amplification.
Western blotting
Cells were lysed in RIPA buﬀer (50 mM Tris–HCl
pH 7·2, 0·1% SDS, 1% Nonidet P-40, 150 mM NaCl
and 1% deoxycholic acid) containing protease inhibitor
cocktail (Complete, Roche), homogenized by sonication
(three 15-s bursts) and centrifuged at 18 400g for
5 min, after 20 min on ice. The protein concentration of
the supernatants was determined by BCA protein assay
(Pierce Biotechnology, Rockford, IL, USA). Equal
amounts of each sample (30 µg or 60 µg) were separated by
10% SDS-PAGE and transferred to nitrocellulose mem-
branes (Amersham). After blocking in 5% non-fat milk in
phosphate-buﬀered saline (PBS) containing 0·2% Tween
20, blots were incubated with antibody anti-GHS-R
(GHSR11-S, Alpha Diagnostic, S. Antonio, TX, USA)
1:1000, followed by reaction with secondary anti-rabbit
horseradish peroxidase (HRP)-conjugate and ECL
detection (Pierce Supersignal, Pierce).
Drugs
Hexarelin (HEXA), EP-40737 (-Thr--Trp(2-Me)-
Ala-Trp--Phe-Lys-NH2) and ghrelin were a kind gift
from Dr Romano Deghenghi (Europeptides, Argenteuil,
France), and have been prepared by conventional solid-
phase synthesis and purified to at least 98% purity by
high-performance liquid chromatography by Neosystem
(Strasbourg, France).
Statistical analysis
Statistical analysis was performed with a statistics package
(PRISM, GraphPad Software, San Diego, CA, USA). All
data are represented as the meanS.E.M. Diﬀerences
between groups were assessed by one-way analysis of
variance (ANOVA) followed by Dunnett’s t-test, with a
probability of P<0·05 considered statistically significant.
Results
Osteoblast proliferation
The viability of cells and the correct setting of culture
conditions were tested by stimulating cell proliferation
Figure 1 Effect of different concentrations of ghrelin (A), hexarelin
(B) and EP-40737 (C) on cultured rat osteoblasts proliferation.
Data are expressed as a percentage of [3H]thymidine incorporated
into nonactively growing fetal rat osteoblasts at 24 h (controls,
shaded bars). MeansS.E.M. of 3–9 samples from the same cell
population are reported. aP<0·05, bP<0·01 vs controls.
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with DMEM containing 10% FCS. In these wells,
[3H]thymidine incorporation was significantly increased
up to 300% over that of controls (data not shown).
Figure 1 shows the eﬀect of ghrelin, HEXA and
EP-40737 on osteoblast proliferation. At a concentration of
1010 M, both ghrelin and HEXA induced a significant
stimulation of osteoblast proliferation, that reached an
increase of 33% and 21% respectively over controls
(P<0·05). The stimulation of proliferation did not increase
further when the concentration of the peptides was
elevated to 109 M (Fig. 1A,B).
Surprisingly, EP-40737 showed an antiproliferative
eﬀect in calvarial osteoblasts. In fact, when the cells
were incubated with 108 and 109 M EP-40737 the
incorporation of [3H]thymidine decreased significantly to
approximately 40% of that measured in controls (P<0·05;
Fig. 1C).
Alkaline phosphatase activity and osteocalcin production
To ascertain whether ghrelin and synthetic GHS are
capable of aﬀecting osteoblastic cell diﬀerentiation, we
measured the changes in ALP activity and OC production
in vitro.
As shown in Fig. 2, ghrelin increased ALP activity in
osteoblasts with a typical bell-shaped curve, and the
maximal eﬀect was reached when cells were incubated
with 1010 M ghrelin (P<0·05 vs controls, Fig. 2A). A
similar curve was seen after addition of HEXA to cultured
osteoblasts. In this case, however, the maximal stimulatory
eﬀect on ALP was reached at 109 M HEXA (P<0·05 vs
controls, Fig. 2B). At variance with these peptides, the
stimulation of ALP activity by EP-40737 was less marked
and never reached statistical significance (Fig. 2C).
Responsiveness of the cells was confirmed by the
addition of 109 M Vit D; in our setting this concen-
tration significantly decreased (P<0·05) ALP specific
activity to 65% of controls.
Figure 3 shows the results obtained by measuring OC
production from cultured osteoblasts. As expected, Vit D
at 109 M induced a significant increase of OC secretion.
Both ghrelin and HEXA induced a consistent rise in OC
secretion into the medium, although at diﬀerent concen-
trations (Fig. 3A,B). A bell-shaped curve was obtained as
a result of cell incubation with ghrelin, and the highest
eﬀect was obtained when the peptide was used at the
concentration of 109 M. In contrast, HEXA was
maximally eﬀective at the lowest concentration tested
(10
11 M).
Figure 2 Effect of different concentrations of ghrelin (A), hexarelin
(B) and EP-40737 (C) on alkaline phosphatase (ALP) production in
primary cultures of rat osteoblasts. Responsiveness of the cells was
confirmed by the addition of 109 M Vit D. Data are expressed
as a percentage of controls. Means+S.E.M. of 3–9 replicates are
reported. aP<0·05 vs controls.
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Also in this instance, EP-40737 did not share the eﬀects
of the other GHS and did not significantly stimulate OC
production from cultured osteoblasts (Fig. 3C).
GHS receptor expression in osteoblasts
The expression of specific mRNA for GHS receptor in
fetal calvaria cells was investigated by using a standard
RT-PCR. Amplification of GHS receptor mRNA gave
rise to a sharp band of the expected length of 288 bp in
calvaria cells harvested from passages 1 to 10 (Fig. 4). The
eﬀective translation of mRNA into the corresponding
protein was demonstrated by Western blot from passages 5
to 10 (Fig. 5). In fact, a specific band of 44 kDa corre-
sponding to the molecular weight demonstrated for the
GHS receptor was present in all samples. Interestingly, at
passage 10, a second band was strongly and specifically
recognized by the anti-GHS receptor antibody, but its
nature remains unknown (Fig. 5).
Discussion
Results of the present research are the first direct demon-
stration that rat calvarial osteoblasts express GHS-R1a
receptors, considered the functional receptor for natural
and synthetic GHS. The receptor has been detected by
RT-PCR and by Western blot from the 1st to the 10th
passage of osteoblasts. Furthermore, the present results
demonstrate that ghrelin and HEXA stimulate osteoblast
replication and increase ALP and OC production.
Previous reports have shown that both ghrelin and
HEXA recognize with the same aﬃnity the functional
GHS-R1a receptor and that activation of this receptor
stimulated an increase in [Ca2+]i (intracellular calcium)
and in IP3 generation (Root & Root 2002). The eﬀects of
GHS on these second messengers correlate with their
stimulatory eﬀects on osteoblast proliferation since stimu-
lation of the PI/[Ca2+]i signal pathways are generally
associated with increased DNA and collagen synthesis
(Yamaguchi et al. 1988).
One intriguing finding is that ghrelin and HEXA
stimulated osteoblast proliferation in a fashion that was not
directly dose-dependent. In fact, the maximal stimulatory
activity of ghrelin and HEXA was observed at a low
concentration (1010 M) but not at higher concentrations
(108 and 109 M). It could be speculated that by
increasing the dose, the peptides could recognize diﬀerent
receptor subtypes having inhibitory proliferative activity
thus tempering the stimulatory action prevailing at low
concentrations. Supporting this view are the results ob-
tained with EP-40737, showing that the peptide exerts an
inhibitory activity on cell proliferation when added at high
concentrations. In this context it is worth noting that
diﬀerent binding aﬃnities have been shown for ghrelin
and HEXA on GHS-1a receptor (Guerlavais et al. 2003,)
Figure 3 Effect of different concentrations of ghrelin (A), hexarelin
(B) and EP-40737 (C) on osteocalcin (OC) production in primary
cultures of rat osteoblasts. Vit D (109 M) was added as a
control. Data are expressed as a percentage of controls.
MeansS.E.M. of 3–9 replicates are reported. aP<0·05, bP<0·01 vs
controls.
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and that either stimulatory (Pettersson et al. 2002, Jeﬀery
et al. 2003) or inhibitory (Ghè et al. 2002) eﬀects on cell
proliferation have been reported for these peptides.
The fact that EP-40737 behaves diﬀerently from these
peptides could be related to the ability of the compound to
recognize only the receptor subtype involved in anti-
proliferative activity. Accordingly EP-40737 does not
share all the biological activities of ghrelin and HEXA
(Torsello et al. 1998, 2000).
In agreement with the diﬀerent eﬀects of the three
GHS on osteoblast proliferation, EP-40737 does not
modify the biochemical markers of osteoblast diﬀerentia-
tion, whereas ghrelin and HEXA significantly stimulate
ALP activity and OC production. It would appear, there-
fore, that both the synthetic HEXA and the alleged natural
ligand of the GHS receptors, ghrelin, modulate osteo-
blast diﬀerentiation. It has been reported that diﬀerent
signalling molecules are responsible for the regulation of
osteoblast diﬀerentiation (Hakeda et al. 1987, Boguslawski
et al. 2000) and it is known that ALP and OC production
reflect diﬀerent aspects of osteoblast diﬀerentiation and
function. Thus it is likely that, by binding the GHS-R1a,
ghrelin and HEXA could activate multiple signalling
pathways that regulate, with diﬀerent sensitivity, the
osteoblastic functional activity. However, further investi-
gations will be required to establish the mechanisms of
GHS actions on osteoblast function and second messenger
generation.
In line with this view, HEXA administered in vivo
completely prevented the early decrease in serum
ALP concentrations in gonadectomized rats, as a likely
consequence of the direct activation of this enzyme in
osteoblasts.
What would be the significance of these findings and
what would happen in physiological conditions? The most
likely agonist candidate for the GHS receptors on osteo-
blasts would be ghrelin. It has been known for a long
Figure 4 Expression of GHS-R1a mRNA in calvarial osteoblasts. Primary cultures of calvaria
cells were harvested from passages 1 to 10. Total RNA extraction and RT-PCR were
performed as described in Materials and Methods. Specific primers for GHS-R1a amplified
a single band of the expected length of 288 bp in all samples (35 cycles). The lower panel
shows amplification of GAPDH in aliquots of the same RT of the corresponding samples in
the panel above. MWM, molecular weight marker; CT, control.
Figure 5 Characterization of GHS receptor protein expression in
calvaria cells. The cellular receptor expression was determined by
Western blot as described in Materials and Methods. Calvaria cells
were harvested from passages (p) 5 to 10. The 44 kDa band
corresponds to the GHS receptor. A representative Western blot
is shown.
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time that gastrectomy causes osteopaenia in experimental
animals (Bussabergher et al. 1938, Ivy 1940, Rümenappf
et al. 1997). Although a deficiency in calcium may
contribute, it is unlikely that gastrectomy-evoked
osteopaenia simply reflects calcium deficiency, since
supplementation with CaCl2 did not prevent the bone loss
(Klinge et al. 1995, Rümenappf et al. 1997). The results
support the view that the stomach is important for bone
metabolism through mechanisms other than the regulation
of intestinal calcium absorption. Interestingly enough,
Lehto-Axtelius et al. (1998) demonstrated that the acid-
producing (oxyntic) mucosa, which produces the most
ghrelin, is the most important for bone metabolism. In
view of these findings, we can suggest that ghrelin secreted
from the stomach is conveyed through the circulation to its
receptors located on bone.
An alternative hypothesis would be that the same bone
cells are the source of ghrelin that would exert its eﬀect
through paracrine or autocrine mechanisms in a similar
way as other local factors (cytokines, growth factors,
prostaglandins, nitric oxide) (Canalis 1996). This view is
supported by the single abstract report by Komatsu et al.
(2000) who detected the ghrelin gene transcript in several
diﬀerent regions of mouse bone, including vertebrae, tibia,
sternum and primary osteoblasts from calvaria.
At variance with our data, Sun et al. (2003) reported no
role for ghrelin in the maintenance of bone density since
ghrelin-null mice had normal bone mineral density and
bone mineral content. Interestingly enough, food intake,
body composition and reproductive function in these mice
also did not diﬀer from the wild-type littermates.
In view of the important regulatory role of ghrelin
demonstrated for all these functions (van der Lely et al.
2004) it is likely that ghrelin-null mice would develop
some compensatory mechanisms to overcome the lack of
the peptide. However, it should be emphasised that
evaluation of bone mineral density does not provide any
information on osteoblast activity. In fact, the biochemical
markers of osteoblast function, osteocalcin and ALP, were
not determined in the ghrelin-null mice. Therefore, the
possible physiological role of ghrelin in the control of
osteoblast function cannot be ruled out and deserves
further in vivo studies.
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